Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review

Abstract

Keywords

acquired perforating dermatoses acquired reactive perforating collagenosis biologic therapy Janus kinase inhibitors infliximab dupilumab tofacitinib transepidermal elimination drug-associated dermatoses

Get full access to this article

View all access options for this article.

References

García-Malinis

Del Valle Sánchez

Sánchez-Salas

Del Prado

Coscojuela

Gilaberte

Acquired perforating dermatosis: clinicopathological study of 31 cases, emphasizing pathogenesis and treatment. J Eur Acad Dermatol Venereol. 2017;31(10):1757-1763. doi:10.1111/jdv.14220

Tsutsui

Namikawa

Mori

, et al. Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. J Dermatol. 2021;48(2):e114-e115. doi:10.1111/1346-8138.15718

Guo

Zeng

Jin

HZ.

Reactive perforating collagenosis treated with dupilumab: a case report and literature review. Dermatol Ther. 2022;35(12):e15916. doi:10.1111/dth.15916

Yuan

Zhou

Liu

Tofacitinib for treatment of acquired reactive perforating collagenosis. JAMA Dermatol. 2025;161(4):446-448. doi:10.1001/jamadermatol.2024.6280